ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)

Market Cap	60.37M
Revenue (ttm)	10.24M
Net Income (ttm)	-47.19M
Shares Out	3.53M
EPS (ttm)	-19.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,258
Average Volume	15,370
Open	15.82
Previous Close	16.60
Day's Range	15.82 - 17.12
52-Week Range	15.66 - 34.20
Beta	2.64
RSI	42.16
Earnings Date	Nov 13, 2025

About STO:EXPRS2

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company’s lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalovirus vaccine program to treat infectious diseases, as well as vaccines for Nipah virus, Malaria, and influenza. In addition, the company offers a huma...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 18
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EXPRS2

Financial Performance

In 2024, STO:EXPRS2's revenue was 7.83 million, a decrease of -11.07% compared to the previous year's 8.80 million. Losses were -36.04 million, -60.57% less than in 2023.